Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmidt maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $58 to $56.
Guggenheim analyst Michael Schmidt maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $58 to $56.